Strategic partnership Leverage MetaVia's strong backing from Dong-A ST Co. Ltd. to position co-development, research collaboration, or regional manufacturing partnerships in Asia, particularly for obesity and MASH programs.

Phase 1 momentum capitalize on DA-1726 Phase 1 MAD results and upcoming Q4 2026 topline data to engage with CROs, payers, and academic collaborators for expanded trial networks and potential early-access discussions.

Liver/metabolic focus Target hepatology and metabolic disease stakeholders with vanoglipel’s preclinical and Phase 2a hepatic actions to explore co-therapies, combination regimens, and sponsor opportunities in NASH/MASH treatment pipelines.

Clinical expansion Identify centers of excellence and high-volume obesity and obesity-related comorbidity sites to accelerate trial recruitment, while offering investigator-initiated study options and early-Phase access programs.

Commercial readiness Prepare for early market access discussions by mapping potential pricing, reimbursement paths, and serviceable markets in cardiometabolic diseases, leveraging MetaVia’s once-weekly OXM/GCGR dual agonist profile to differentiate from GLP-1 alone therapies.